Anti-Glomerular Basement Membrane (anti-GBM) Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Anti-Glomerular Basement Membrane (anti-GBM) Disease Market Outlook

Thelansis’s “Anti-Glomerular Basement Membrane (anti-GBM) Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Anti-Glomerular Basement Membrane (anti-GBM) Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Anti-Glomerular Basement Membrane (anti-GBM) Disease Overview

Anti-Glomerular Basement Membrane (anti-GBM) Disease is a rare form of small vessel vasculitis that affects the kidney and lung capillary beds. It is an archetypic autoimmune disease caused by the development of directly pathogenic autoantibodies targeting a well-characterized autoantigen expressed in the basement membranes of these organs. The body creates autoantibodies that recognize and attach to the basement membrane, which is part of the wall of capillary blood vessels in the kidneys and lungs. Once the autoantibodies bind to the basement membrane, this creates a signal to the body’s immune system to attack. However, the inciting events that induce the autoimmune response. In genetically susceptible individuals, environmental factors, such as the current infection, may trigger the disease. Most patients develop widespread glomerular crescent formation, presenting with signs and symptoms of rapidly progressing GN, and 40%–60% will have an alveolar hemorrhage at the same time. Treatment focuses on removing pathogenic autoantibody as quickly as possible, typically with plasma exchange, steroids, and cytotoxic therapy to stop ongoing autoantibody production and tissue inflammation. The body creates autoantibodies that recognize and attach to the basement membrane, which is part of the wall of capillary blood vessels in the kidneys and lungs. Once the autoantibodies bind to the basement membrane, this creates a signal to the body’s immune system to attack.

• The incidence of Anti-Glomerular Basement Membrane (anti-GBM) Disease cases ranges from 0.76 to 1.75 cases per million population in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: